Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Sponsor: Shanghai Tong Ren Hospital
Summary
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.
Official title: Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2021-04-12
Completion Date
2025-10
Last Updated
2025-05-21
Healthy Volunteers
No
Interventions
PCSK9 inhibitor (Alirocumab)plus standard medications
PCSK9 inhibitor(Alirocumab) was giving to subjects before PPCI and continued twice a month until 3 month after AMI
standard medications
standard medications was giving to subjects according guidelines
Locations (2)
Tongren Hospital, Shanghai
Shanghai, Shanghai Municipality, China
Shanghai tenth people's hospital
Shanghai, China